Tucidinostat is used in the treatment of Adult T-cell leukaemia-lymphoma, Breast cancer, Peripheral T-cell lymphoma,Brain metastases, Diffuse large B cell lymphoma and malignant melanoma.
It also used in HIV cure strategies. Tucidinostat was developed by Shenzhen Microchip Biological Sci. & Tech. Co. Ltd..
The API has now reached off-patent status, after being launched in 2014.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Tucidinostat and many others, contact info@pharmacheminvestor.com